EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?

Piotr Ryszkiewicz iD, Eberhard Schlicker, Barbara Malinowska iD

Antioxidants · 21.03.2025 · 14 (4) · 377

DOI: 10.3390/antiox14040377 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 21.03.2025. Verfasst von Piotr Ryszkiewicz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Mickiewicz Str. 2A, 15-222 Bialystok, Poland. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, Medical University of Białystok, National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension (PH) is a progressive disease characterized by elevated blood pressure in the pulmonary arteries, associated also with inflammation and oxidative stress. Inducible nitric oxide synthase (iNOS) is one of the key mediators of inflammation and immune system activation. Although preclinical studies mostly suggest a detrimental role of iNOS overactivation in PH, there is a lack of exhaustive analyses and summaries. Therefore, this literature overview aims to fill this gap. The involvement of iNOS in the pathogenesis of the four main clinical groups of PH is discussed to assess whether targeting iNOS could be a promising way to treat PH. iNOS expression patterns in the organs primarily affected by PH are analyzed both in animals and in humans. Consequently, the effectiveness of pharmacological iNOS inhibition and/or iNOS gene deletion is discussed and compared, also with reference to the activity of constitutive NOS isoforms, particularly endothelial NOS (eNOS). Overall, our overview suggests that selective iNOS inhibitors could be considered as a novel treatment strategy for PH, as decreases in right ventricular and pulmonary artery pressure, the alleviation of ventricular hypertrophy, and improvements of pulmonary and cardiac function were observed, among others. Nevertheless, further research efforts in this area are needed.

Schlagwörter

Stichwörter der Autor:innen

animal modelscardiovascular systemenzyme inhibitioninducible nitric oxide synthaseinflammationnitric oxidenitrosative stressoxidative stresspulmonary arterial hypertensionpulmonary hypertension

Autor:innen und Institutionen

  • Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Mickiewicz Str. 2A, 15-222 Bialystok, Poland.
  • Department of Pharmacology and Toxicology, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany.

ORCID-Profile: Piotr Ryszkiewicz, Barbara Malinowska

Förderung

  • National Science Center
  • Medical University of Białystok
  • National Science Centre, Poland

Zitieren

APA

Ryszkiewicz, P., Schlicker, E., & Malinowska, B. (2025). Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?. Antioxidants, 14(4), 377. https://doi.org/10.3390/antiox14040377

Vancouver

Ryszkiewicz P, Schlicker E, Malinowska B. Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?. Antioxidants. 2025;14(4):377. doi:10.3390/antiox14040377

BibTeX
@article{Ryszkiewicz2025,
  author = {Ryszkiewicz, Piotr and Schlicker, Eberhard and Malinowska, Barbara},
  title = {Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?},
  journal = {Antioxidants},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {377},
  doi = {10.3390/antiox14040377}
}
Kostenlos starten →